Oncology Today with Dr Neil Love

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:
Introduction (0:00)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)
Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)
CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)
Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24)
Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47)

CME information and select publications

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics:
Introduction (0:00)
Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42)
Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23)
Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01)
Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22)
Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37)

CME information and select publications

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:
Introduction (0:00)
The Biopathophysiology of Myelofibrosis (MF) (2:19)
Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)
Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)
Upcoming at European Hematology Association (EHA) 2026 (49:22)

CME information and select publications

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:
Introduction (00:00)
Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
Strategies to Prevent and Manage Hyperglycemia (27:02)
Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
Mitigation and Management of Gastrointestinal Adverse Events (51:05)
Management of Dermatologic Adverse Events (59:58)
Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:
Introduction (0:00)
Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)
Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24)
Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28)
Management of Limited-Stage SCLC — Dr Ganti (1:31:54)

CME information and select publications